We describe a protocol for using bone morphogenetic protein-7 (BMP-7) or Matrigel to selectively induce dendritic growth in primary sympathetic neurons dissociated from the superior cervical ganglia (SCG) of perinatal rats.
The shape of the dendritic arbor determines the total synaptic input a neuron can receive 1-3, and influences the types and distribution of these inputs 4-6. Altered patterns of dendritic growth and plasticity are associated with impaired neurobehavioral function in experimental models 7, and are thought to contribute to clinical symptoms observed in both neurodevelopmental disorders 8-10 and neurodegenerative diseases 11-13. Such observations underscore the functional importance of precisely regulating dendritic morphology, and suggest that identifying mechanisms that control dendritic growth will not only advance understanding of how neuronal connectivity is regulated during normal development, but may also provide insight on novel therapeutic strategies for diverse neurological diseases.
Mechanistic studies of dendritic growth would be greatly facilitated by the availability of a model system that allows neurons to be experimentally switched from a state in which they do not extend dendrites to one in which they elaborate a dendritic arbor comparable to that of their in vivo counterparts. Primary cultures of sympathetic neurons dissociated from the superior cervical ganglia (SCG) of perinatal rodents provide such a model. When cultured in defined medium in the absence of serum and ganglionic glial cells, sympathetic neurons extend a single process which is axonal, and this unipolar state persists for weeks to months in culture 14,15. However, the addition of either bone morphogenetic protein-7 (BMP-7) 16,17 or Matrigel 18 to the culture medium triggers these neurons to extend multiple processes that meet the morphologic, biochemical and functional criteria for dendrites. Sympathetic neurons dissociated from the SCG of perinatal rodents and grown under defined conditions are a homogenous population of neurons 19 that respond uniformly to the dendrite-promoting activity of Matrigel, BMP-7 and other BMPs of the decapentaplegic (dpp) and 60A subfamilies 17,18,20,21. Importantly, Matrigel- and BMP-induced dendrite formation occurs in the absence of changes in cell survival or axonal growth 17,18.
Here, we describe how to set up dissociated cultures of sympathetic neurons derived from the SCG of perinatal rats so that they are responsive to the selective dendrite-promoting activity of Matrigel or BMPs.
1. Preparation of Culture Medium (C2 medium)
Amount | Component | Final Concentration |
190 ml | DMEM (low glucose) | N/A |
10 ml | fatty acid free BSA (20mg/ml in DMEM) | 50 μg/ml |
2.8 ml | L-Glutamine | 1.4 mM |
4 ml | insulin/transferrin/selenium(100x) | 10 μg/ml insulin 5.5 μg/ml transferrin 38.7 nM selenium |
0.4 ml | NGF (125 μg/ml) | 100 ng/ml |
200 ml | Ham F-12 | N/A |
2. Preparation of Glass Coverslips
3. Preparation of Coverslips for Culture
4. Dissection and Isolation of the Superior Cervical Ganglion
5. Feeding and Maintenance of Cultures
6. Inducing Dendritic Growth with Matrigel or BMP-7
7. Immunocytochemical Analysis of BMP-7-induced Dendritic Growth
8. Representative Results
Sympathetic neurons dissociated from the SCG of perinatal rats and grown in the absence of serum and ganglionic glial cells fail to extend MAP2 immunopositive processes (Figure 1), but rather, typically extend only a single axonal process 14,15. Exposure to BMP-7 (Figure 1) or Matrigel induces the formation of numerous processes that meet the morphological, biochemical and functional criteria of dendrites 17,18. The dendrite-promoting activity of either Matrigel or BMP-7 is concentration- and time-dependent 17,18,20. Maximal dendritic growth is observed using concentrations of Matrigel between 50 and 75 μg/ml or BMP-7 between 30 and 100 ng/ml, and half-maximal effects are typically observed at BMP-7 concentrations of ~2 ng/ml. However, significant changes in dendritic growth can be detected with BMP-7 concentrations as low as 300 pg/ml. The dendritic response to either Matrigel or BMP-7 is relatively slow, with <50% of the neurons forming a second process within 24 hours after exposure to either dendrite-promoting agent. However, within 3 days after the initial BMP-7 exposure, virtually all neurons respond to maximally effective Matrigel or BMP-7 concentrations. The number of dendrites per neurons continues to increase with continuous exposure to BMP-7, with most of the change occurring during the first 10 days of treatment. After 4 weeks, BMP-7-treated neurons typically have 6-8 primary dendrites that exhibit secondary, tertiary and even quaternary dendritic branches 17. This increase in dendritic arbor occurs in the absence of any significant change in axonal growth, and comparable dendritic responses can be elicited using similar concentrations of BMPs 2, 4, 5 or 6 20,21. Dendritic growth can also be elicited by co-culturing sympathetic neurons with endogenous ganglionic glial cells 15,22; however, the dendritic response is significantly slower under these conditions.
Figure 1. BMP-7 promotes dendritic growth in cultured sympathetic neurons. Non-neuronal cells were eliminated from SCG cultures by treatment with anti-mitotic for 48 hr beginning on day 2 in vitro. Beginning on day 5 in vitro, cultures were treated with either control medium (A) or medium supplemented with BMP-7 at 50 ng/ml (B). On day 11 in vitro (after 5 days of BMP treatment), cultures were immunostained with mAb against MAP2, a protein found primarily in dendrites and neuronal somata. As shown in representative fluorescence photomicrographs, neurons grown under control conditions lack dendrites as evidenced by the lack of MAP-2 immunopositive processes dendrites (A); in contrast, neurons exposed to BMP-7 (B) typically have several tapered MAP-2 immunopositive dendrites.
The advantages of this model include: (a) the cultures are comprised of a homogenous population of sympathetic neurons devoid of other cell types 17,23; (b) the growth factor requirements of sympathetic neurons are well-established, which allows the use of defined medium, and a variety of defined media, and substrates work well for growing and maintaining sympathetic neurons 23; (c) neurons in these cultures respond uniformly to the dendrite-promoting activity of Matrigel, BMP-7 and other BMPs of the dpp and 60A subfamilies 17,18,20,21; and (d) Matrigel- or BMP-induced dendrite formation occurs in the absence of changes in cell survival or axonal growth 17,18. This model allows experimental control of when dendritic growth is triggered, which make it possible to obtain synchronized populations of neurons at distinct stages of dendritic growth, e.g., immediately preceding the formation of dendrites, during primary dendritogenesis (the initial formation of primary dendrites) and during later stages of dendritic maturation. The most significant limitations of the model include the limited amounts of RNA and protein available from a typical dissection of a single litter, which may restrict biochemical studies, and some difficulty in manipulating gene expression. Recent advances in techniques for expressing cDNA in primary neuronal cell cultures are rapidly overcoming this latter disadvantage. There are publications reporting the successful application of lipid-based delivery systems, nucleofection, and adenoviral vectors to cultured sympathetic neurons. The reported transfection efficiencies are relatively low (typically ranging from 10-20% with lipofection or nucleofection and up to 30-50% with viral infection), which is adequate for endpoints based on individual cell analyses, such as morphological analyses, but may be problematic for many biochemical endpoints.
Factors that can interfere with BMP-induced dendritic growth in cultured sympathetic neurons include culturing the neurons at a very high cell density and including serum in the culture media. While the reason that high cell density attenuates the dendrite-promoting activity of BMPs is not known, it is likely that serum attenuates this activity because BMPs bind avidly to serum proteins. Interestingly, serum itself has weak dendrite-promoting activity in cultured sympathetic neurons 24, and our preliminary data suggests that this activity is mediated by BMPs, which are present in most if not all commercial sera. BMPs are also present in Matrigel, and likely mediate its dendrite-promoting activity. A third factor that can impact the dendrite-promoting activity of BMPs is improper handling and storage of BMPs. Do not store BMP stock solutions at a concentration of less than 0.1 mg/ml. It is important to not let BMP stock or working solutions to become very basic and we recommend that buffers used to dilute stock solutions have a pH of 4.5 ± 0.05. Mix all solutions vigorously before aliquoting but not so vigorously that solutions foam, and only use polypropylene tubes because BMPs tend to stick to other plastics. Do not store aliquots in freezers that have an automatic defrost feature because the cycling of temperatures is sufficient to destroy activity of BMP-7. It is strongly advised that BMP solutions be stored at -80 °C and that freeze-thawing be minimized (we do not freeze-thaw more than 2-3 times). Similar precautions should be used in handling Matrigel. Also, it is recommended that Matrigel be slowly thawed at 4 °C. Matrigel will not induce dendritic growth when used to precoat substrates prior to plating neurons; it is only effective when added to the culture medium of established neuronal cell cultures 18.
The authors have nothing to disclose.
This work was supported by funding from the National Institutes of Health (grants R21 NS45037 and R01 ES014901).
Name of the reagent | Company | Catalogue number | Comments |
Glass coverslips | Bellco | 1943-10012 | 12 mm Round Coverslip #1 Thickness, German glass |
Bent tip pipets | Bellco | 1273-50003 | |
Poly-D-lysine | Sigma | P0899-100MG | Stock solution 1 mg/ml |
Distilled water | Gibco | 15230 | |
Fine forceps Dumont no. 4 and 5 | Fine Science Tools (FST) | 11252-30 11241-30 | |
20-gauge needles | Becton Dickinson | 305176 | |
Leibovitz’s L-15 medium | Invitrogen | 11415 | |
Collagenase | Worthington | 4176 | 1 mg/ml |
Dispase | Roche | 04942078001 | 5 mg/ml |
Hank’s balanced salt solution( -Ca,-Mg) | Invitrogen | 14185-052 | |
DMEM Low glucose | Invitrogen | 11885 | |
L-Glutamine | Invitrogen | 25030 | 20 mM |
Insulin/Transferrin/ Selenium | Invitrogen | 51500-056 | 100X |
Fatty-acid free BSA | Calbiochem | 126609 | |
NGF | Harlan Bioproducts | 5017 | |
Ham F-12 nutrient medium (F-12) | Invitrogen | 11765 | |
Cytosine arabinoside | Sigma | C1768 | |
Matrigel | BD Biosciences | 356234 | Avoid repeated freeze-thaw cycles |
BMP-7 | R&D Systems Curis, Inc. | 345-BP BMP7-07H | BMPs 4, 5 and 6 work equally as well as BMP-7 and are sometimes easier to obtain commercially |
Paraformaldehyde | Sigma | P6148 | |
Triton X-100 | Fisher | BP151-500 | |
Mouse anti-rat MAP2 antibody | Sternberg Monoclonals Inc. | SMI52 | 1/5000 |
Alexa Fluor 546 goat-anti-mouse | Invitrogen | A11003 | 1/10000 |
Mounting media | Prolong Antifade kit Molecular Probes | P7481 |
Table 1. Materials.